[go: up one dir, main page]

BR0014869A - Composição e método para estabilização da mesma - Google Patents

Composição e método para estabilização da mesma

Info

Publication number
BR0014869A
BR0014869A BR0014869-5A BR0014869A BR0014869A BR 0014869 A BR0014869 A BR 0014869A BR 0014869 A BR0014869 A BR 0014869A BR 0014869 A BR0014869 A BR 0014869A
Authority
BR
Brazil
Prior art keywords
composition
stabilizing
glyceride
new
bicyclic compound
Prior art date
Application number
BR0014869-5A
Other languages
English (en)
Other versions
BRPI0014869B8 (pt
BRPI0014869B1 (pt
Inventor
Ryuji Ueno
Tsuyoshi Habe
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22573018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0014869A publication Critical patent/BR0014869A/pt
Publication of BRPI0014869B1 publication Critical patent/BRPI0014869B1/pt
Publication of BRPI0014869B8 publication Critical patent/BRPI0014869B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Patente de Invenção: "COMPOSIçãO E MéTODO PARA ESTABILIZAçãO DA MESMA". Uma nova composição é descrita compreendendo um novo composto bicíclico, que é esperado ser farmaceuticamente ativo, e um glicerídeo. A estabilidade do composto bicíclico pode ser significantemente melhorada dissolvendo-se o mesmo em um glicerídeo.
BRPI0014869A 1999-10-15 2000-10-13 prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização BRPI0014869B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15954999P 1999-10-15 1999-10-15
US60/159,549 1999-10-15
PCT/JP2000/007109 WO2001027099A2 (en) 1999-10-15 2000-10-13 Bicyclic compounds composition and method for stabilizing the same

Publications (3)

Publication Number Publication Date
BR0014869A true BR0014869A (pt) 2002-06-25
BRPI0014869B1 BRPI0014869B1 (pt) 2017-06-13
BRPI0014869B8 BRPI0014869B8 (pt) 2021-05-25

Family

ID=22573018

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014869A BRPI0014869B8 (pt) 1999-10-15 2000-10-13 prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização

Country Status (26)

Country Link
US (5) US6583174B1 (pt)
EP (2) EP1220849B1 (pt)
JP (2) JP4332316B2 (pt)
KR (1) KR100830061B1 (pt)
CN (1) CN1268623C (pt)
AR (3) AR026046A1 (pt)
AT (2) ATE267189T1 (pt)
AU (2) AU780342B2 (pt)
BR (1) BRPI0014869B8 (pt)
CA (1) CA2385732C (pt)
CZ (1) CZ303625B6 (pt)
DE (2) DE60039727D1 (pt)
DK (2) DK1426361T4 (pt)
ES (2) ES2221859T3 (pt)
HK (2) HK1066792A1 (pt)
HU (2) HU230484B1 (pt)
IL (2) IL148803A0 (pt)
MX (1) MXPA02003756A (pt)
NO (1) NO330258B1 (pt)
NZ (1) NZ518020A (pt)
PT (2) PT1426361E (pt)
RU (1) RU2695274C3 (pt)
TR (1) TR200201032T2 (pt)
TW (1) TWI281918B (pt)
WO (1) WO2001027099A2 (pt)
ZA (1) ZA200202312B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268623C (zh) * 1999-10-15 2006-08-09 苏坎波公司 组合物和使该组合物稳定的方法
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
PL1871380T3 (pl) * 2005-04-12 2012-03-30 Sucampo Ag Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych
BRPI0707334B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
EP2682130A1 (en) * 2006-01-24 2014-01-08 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
KR101437302B1 (ko) * 2006-02-07 2014-09-02 가부시키가이샤 아루떼꾸 우에노 프로스타글란딘 유도체의 제조 방법
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
AU2008276840B2 (en) * 2007-07-19 2013-10-03 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
ES2567328T3 (es) 2009-07-28 2016-04-21 Ono Pharmaceutical Co., Ltd. Compuesto bicíclico y uso del mismo para fines médicos
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
CA2779736A1 (en) 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
ES2581852T3 (es) * 2011-01-27 2016-09-07 Ono Pharmaceutical Co., Ltd. Compuesto bicíclico y uso del mismo para fines médicos
EP2669279B1 (en) 2011-01-27 2017-01-11 ONO Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
JP6954282B2 (ja) 2016-06-30 2021-10-27 小野薬品工業株式会社 二環式化合物の製造方法
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
JPWO2019221215A1 (ja) * 2018-05-18 2021-05-27 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
JP7518661B2 (ja) 2020-05-14 2024-07-18 沢井製薬株式会社 ルビプロストン含有整粒物、ルビプロストン含有錠剤およびそれらの製造方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18202A (en) * 1857-09-15 Improvement in feathering paddle-wheels
JPS5720305B2 (pt) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
US3966962A (en) 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5919524B2 (ja) 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
CA1184906A (en) * 1977-04-19 1985-04-02 Roy A. Johnson 9-deoxy-5,9-epoxy-prostaglandins
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS5452717A (en) * 1977-09-29 1979-04-25 Chugai Pharmaceut Co Ltd Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d
US4130566A (en) 1977-10-27 1978-12-19 Sumitomo Chemical Company, Limited Process for producing 5-carboxy-2-acetylthiophene
AT358530B (de) 1978-04-25 1980-09-10 Plc Pharma Licences Stabilisierungsverfahren
JPS55136219A (en) 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
JPS59137413A (ja) * 1983-01-25 1984-08-07 Teijin Ltd ７−チアプロスタグランジンｅ↓１類を含有する医薬品組成物
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
GB2210556B (en) 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2597649B2 (ja) † 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
PT90888B (pt) * 1988-06-17 1994-12-30 Wellcome Found Processo para a preparacao de composicoes farmaceuticas contendo prostaglandinas
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
JPH0745504B2 (ja) * 1988-07-29 1995-05-17 株式会社上野製薬応用研究所 プロスタグランジン前駆体およびその製法
JP2794433B2 (ja) 1989-02-02 1998-09-03 丸善製薬株式会社 甘草疎水性フラボノイド製剤
CA2030346C (en) † 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) † 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JPH0446122A (ja) 1990-06-13 1992-02-17 Nippon Iyakuhin Kogyo Kk 活性型ビタミンｄ↓３類含有製剤
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
US5274130A (en) * 1991-09-03 1993-12-28 R-Tech Ueno Ltd. Process for production of prostaglandin intermediates
JP2746800B2 (ja) * 1991-09-03 1998-05-06 株式会社アールテック・ウエノ プロスタグランジン中間体の製法
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
CN1268623C (zh) * 1999-10-15 2006-08-09 苏坎波公司 组合物和使该组合物稳定的方法
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4210631B2 (ja) 2004-06-24 2009-01-21 株式会社日立製作所 ブレーキ制御装置

Also Published As

Publication number Publication date
US6583174B1 (en) 2003-06-24
US20120095090A1 (en) 2012-04-19
ES2309410T3 (es) 2008-12-16
AU2004242503B2 (en) 2007-06-21
CZ303625B6 (cs) 2013-01-16
AU2004242503C1 (en) 2005-01-27
AR026046A1 (es) 2002-12-26
WO2001027099A2 (en) 2001-04-19
HK1045693B (zh) 2005-01-21
CN1268623C (zh) 2006-08-09
KR100830061B1 (ko) 2008-05-16
IL148803A0 (en) 2002-09-12
HUP0203746A2 (hu) 2003-03-28
EP1426361B2 (en) 2015-02-25
NZ518020A (en) 2004-02-27
RU2695274C3 (ru) 2020-11-09
EP1426361B1 (en) 2008-07-30
AU2004242503A1 (en) 2005-01-27
US20080255227A1 (en) 2008-10-16
ATE267189T1 (de) 2004-06-15
NO330258B1 (no) 2011-03-14
RU2695274C9 (ru) 2020-01-22
JP4332316B2 (ja) 2009-09-16
US8097649B1 (en) 2012-01-17
DK1426361T4 (en) 2015-03-16
KR20020068521A (ko) 2002-08-27
US8088934B2 (en) 2012-01-03
HU229547B1 (en) 2014-01-28
HU230484B1 (hu) 2016-07-28
JP2003511445A (ja) 2003-03-25
US20040235885A1 (en) 2004-11-25
ZA200202312B (en) 2002-12-24
AU7685600A (en) 2001-04-23
AR109354A2 (es) 2018-11-21
DK1426361T3 (da) 2008-11-17
NO20021736D0 (no) 2002-04-12
PT1220849E (pt) 2004-10-29
TWI281918B (en) 2007-06-01
MXPA02003756A (es) 2005-09-08
ES2221859T3 (es) 2005-01-16
HK1066792A1 (en) 2005-04-01
EP1426361A1 (en) 2004-06-09
AU780342B2 (en) 2005-03-17
PT1426361E (pt) 2008-10-08
AR089848A2 (es) 2014-09-24
US7417067B2 (en) 2008-08-26
DE60039727D1 (de) 2008-09-11
RU2002112984A (ru) 2004-01-20
ATE402925T2 (de) 2008-08-15
WO2001027099A3 (en) 2001-10-25
CA2385732A1 (en) 2001-04-19
EP1220849B1 (en) 2004-05-19
CN1379769A (zh) 2002-11-13
HUP1300369A2 (pt) 2003-03-28
EP1220849A2 (en) 2002-07-10
DK1220849T3 (da) 2004-09-27
IL148803A (en) 2006-07-05
JP2009235079A (ja) 2009-10-15
NO20021736L (no) 2002-04-12
DE60010913T2 (de) 2005-06-09
BRPI0014869B8 (pt) 2021-05-25
HK1045693A1 (en) 2002-12-06
TR200201032T2 (tr) 2002-08-21
ES2309410T5 (es) 2015-03-17
CA2385732C (en) 2009-02-10
RU2695274C2 (ru) 2019-07-22
CZ20021037A3 (cs) 2002-09-11
HUP0203746A3 (en) 2005-02-28
BRPI0014869B1 (pt) 2017-06-13
DE60010913D1 (de) 2004-06-24

Similar Documents

Publication Publication Date Title
BR0014869A (pt) Composição e método para estabilização da mesma
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BR0010562A (pt) Inibidor de metaloprotease do ácido hidrox mico de sulfona aromática
BR9714310A (pt) Composição farmacêutica
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
NO20026132D0 (no) Sterkt konsentrerte stabile meloxicamlösninger
MY130441A (en) Solutions containing epinastin
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
BR0006045A (pt) Composição que compreende uma carnitina e glutationa, útil para aumentar a absorção de glutationa e para sinergizar seus efeitos
BR0012951A (pt) Agonistas de retinóides seletivos
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
BR0012696A (pt) Composição oftálmica
ECSP045110A (es) Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/10/2020